cached image
Affiliations: | | Terry Fox Research Institute | BC Cancer Agency, Vancouver, British Columbia, Canada |
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Victor Ling is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
1985 — 1992 |
Ling, Victor |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Multidrug Resistance and P-Glycoprotein in Human Cancer @ Ontario Cancer Institute
The objective of this application is to investigate what roles mutations resulting in multidrug resistance play in human cancer. Such mutations are thought to limit successful chemotherapeutic treatment of advanced disease. The immediate aim is to develop sensitive and specific probes for detecting multidrug resistance cells in patient biopsies. This will be accomplished by generating monoclonal antibodies against the 170,000 dalton cell surface P-glucoprotein shown to be expressed in multidrug resistance cells. Heteroantisera against this protein already developed will be used to screen biopsy samples from cancer patients using the highly sensitive immunoblot (Western blot) procedure. DNA sequence specific for human P-glycoprotein will be cloned and used as probes for multidrug resistance mutations. Multidrug-resistant cell will be isolated in vitro from cell lines established from patient tumors. These will be studied and compared with resistant cells found in patients. This program should provide significant information concerning how drug-resistance limits chemotherapeutic treatment of malignancies. It may in addition, provide new vistas for improving therapeutic management.
|
0.933 |
1987 — 1990 |
Ling, Victor |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Multidrig Resistance and P-Glycoprotein @ Ontario Cancer Institute
The objective of this application is to investigate what roles mutations resulting in multidrug resistance play in human cancer. Such mutations are thought to limit successful chemotherapeutic treatment of advanced disease. The immediate aim is to develop sensitive and specific probes for detecting multidrug resistance cells in patient biopsies. This will be accomplished by generating monoclonal antibodies against the 170,000 dalton cell surface P-glucoprotein shown to be expressed in multidrug resistance cells. Heteroantisera against this protein already developed will be used to screen biopsy samples from cancer patients using the highly sensitive immunoblot (Western blot) procedure. DNA sequence specific for human P-glycoprotein will be cloned and used as probes for multidrug resistance mutations. Multidrug-resistant cell will be isolated in vitro from cell lines established from patient tumors. These will be studied and compared with resistant cells found in patients. This program should provide significant information concerning how drug-resistance limits chemotherapeutic treatment of malignancies. It may in addition, provide new vistas for improving therapeutic management.
|
0.933 |